useful for upper GI targeting Troches buccal absorption, limited evidence specific to BPC-157 Who oral delivery is best suited for: Leaky gut / intestinal permeability Inflammatory bowel disease (IBD, Crohn's, ulcerative colitis) NSAID-induced gastric damage or ulcers Irritable bowel syndrome (IBS) General GI maintenance alongside other therapies Patients who cannot or will not self-inject Practical considerations: Oral bioavailability is lower for systemic goals do not expect injection-equivalent tendon or joint results Dosing protocols typically require three to ten times the injectable dose to achieve comparable GI effects Product quality varies widely in the oral supplement market sourcing from a licensed compounding pharmacy is essential Nasal BPC-157: Emerging Option, Limited Evidence Nasal BPC-157 is the third delivery route and the least established
After about four weeks, the dose can be increased to 0.5 mg or more if needed
Oral medications with narrow therapeutic windows : For injectable semaglutide (Ozempic, Wegovy), no clinically significant effect on the absorption of tested oral medications has been observed
In this case, semaglutide mimics the hormone glucagon-like peptide-1 (GLP-1), which is released in the gut during eating to signal a feeling of satiation, so it follows that its now implicated in moderating similar feelings of stress and reward involved in alcohol use
Funding This work was supported by the National Natural Science Foundation (Grant numbers 82170340, 82000333, 82200376, and 82070320)
